Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 261 publications

Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia.

Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia.

Journal: Leukemia research reports
Published: October 02, 2025

Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib

Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025

Microfluidic single-cell drug screening: toward personalized precision therapy in chronic myeloid leukemia.

Microfluidic single-cell drug screening: toward personalized precision therapy in chronic myeloid leukemia.

Journal: Lab on a chip
Published: September 29, 2025

Histopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.

Histopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.

Journal: The American Journal of dermatopathology
Published: September 08, 2025

Asciminib in late-line CML treatment.

Asciminib in late-line CML treatment.

Journal: Blood advances
Published: August 19, 2025

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

Journal: Circulation
Published: August 05, 2025

Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives.

Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives.

Journal: Journal of chemotherapy (Florence, Italy)
Published: July 25, 2025

Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.

Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.

Journal: Haematologica
Published: July 23, 2025

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Journal: Science signaling
Published: July 15, 2025

Splenic Infarction at the Crossroads of Hematologic and Cardioembolic Risk.

Splenic Infarction at the Crossroads of Hematologic and Cardioembolic Risk.

Journal: Cureus
Published: July 15, 2025

Exploring the Allosteric Pathways of Asciminib in the Dual Inhibition of BCR-ABL1.

Exploring the Allosteric Pathways of Asciminib in the Dual Inhibition of BCR-ABL1.

Journal: Biomolecules
Published: July 09, 2025

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia.

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia.

Journal: Hematology reports
Published: July 03, 2025
Showing 1-12 of 261

Last Updated: 10/31/2025